Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of PrimeC in amyotrophic lateral sclerosis
MOH_2019-11-14_007485Phase 2Completed
- Sponsor
- NeuroSense Therapeutics
- Start
- Nov 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PrimeC, celecoxib and ciprofloxacin in amyotrophic lateral sclerosis (ALS), sponsored by NeuroSense Therapeutics. Started Nov 2019; status: completed.
02
Drugs
PrimeCcelecoxibciprofloxacin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on MOH_2019-11-14_007485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-14_007485.